SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach
Search This Board: 
Last Post: 10/7/2017 3:52:07 PM - Followers: 69 - Board type: Free - Posts Today: 0

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
SureTrader
Interactive Brokers Advertisement
NTRP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Neurotrope Provides Business Update and Reports Second Quarter 2017 Financial Results 08/09/2017 08:30:00 AM
NTRP News: Quarterly Report (10-q) 08/08/2017 05:19:08 PM
NTRP News: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 07/19/2017 11:36:00 AM
NTRP News: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 07/19/2017 11:16:00 AM
NTRP News: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting 06/29/2017 09:30:00 AM
PostSubject
#4967  Sticky Note Full 2a trial article. Some incredible and runncoach 05/15/17 05:57:37 PM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#5424   There's no telling what's going on. Nobody runncoach 10/07/17 03:52:07 PM
#5423   Does anyone have any thoughts as to what Marlseg 10/07/17 09:04:26 AM
#5422   No news - nothing happening. XenaLives 10/06/17 10:13:08 PM
#5421   Animals are used in pre-clinical tests for absorption. XenaLives 09/27/17 04:03:44 PM
#5420   Informative. Thx runncoach 09/27/17 01:57:02 PM
#5418   Phase 1 is a safety stage, XenaLives 09/27/17 01:14:08 PM
#5417   The point you keep missing is that the Whatsupp 09/27/17 01:00:27 PM
#5416   Simply check TTPH history to know that oral XenaLives 09/27/17 12:44:15 PM
#5415   The point is that you are wrong about Whatsupp 09/27/17 12:21:45 PM
#5414   Animal testing is not clinical data. It XenaLives 09/25/17 11:53:53 AM
#5413   I guess you can believe whatever you want, Whatsupp 09/25/17 11:51:05 AM
#5411   This is not that hard, animal studies can't XenaLives 09/23/17 04:07:11 PM
#5410   This is not that hard, BS approvals do Whatsupp 09/23/17 11:08:53 AM
#5409   Animal studies do not let you skip studies XenaLives 09/23/17 10:07:34 AM
#5408   Of course you do a trial, a clinical Whatsupp 09/23/17 10:00:45 AM
#5407   They don't have to start over. They runncoach 09/23/17 07:44:07 AM
#5406   Yes - and it concerns oral solutions - XenaLives 09/22/17 09:48:24 PM
#5404   LOL! How do you find out if drug XenaLives 09/22/17 02:46:56 PM
#5403   Yes, oops you were wrong, you stated that Whatsupp 09/22/17 02:05:11 PM
#5402   oops - XenaLives 09/22/17 01:13:49 PM
#5401   You are wrong - This is from the Whatsupp 09/22/17 12:48:59 PM
#5400   Because one is administered IV and the other XenaLives 09/22/17 11:14:36 AM
#5399  Restored Coach - looks to me like some bio Whatsupp 09/22/17 11:14:05 AM
#5398   This was explained months ago. The rules for Whatsupp 09/22/17 11:09:51 AM
#5397   Well they more than doubled their investment last runncoach 09/21/17 04:17:43 PM
#5396   How do you know that "institutions have been XenaLives 09/21/17 04:10:48 PM
#5395   Not from what I've seen, no but that's runncoach 09/21/17 04:05:09 PM
#5394   NTRP didn't do an adaptive trial, so are XenaLives 09/21/17 03:59:58 PM
#5393   I thought everyone was waiting on the new runncoach 09/21/17 12:17:34 PM
#5392   Nothing new for 6 weeks now... XenaLives 09/21/17 10:47:43 AM
#5391   Great summary, thanks for the post. Whatsupp 09/18/17 10:11:01 AM
#5390   https://insiderfinancial.com/neurotrope-inc-nasdaqntrp-is-on-the-road-to-recover grich1 09/18/17 10:01:10 AM
#5389   Thank you Biostudent 09/14/17 07:00:19 PM
#5388   Link to Rodman and Renshaw presentation fyi. runncoach 09/14/17 06:36:44 PM
#5387   Didn't even know the were there. Good runncoach 09/13/17 05:32:27 PM
#5386   Rodman conference Biostudent 09/13/17 05:10:00 PM
#5385   If this was other small cap bios, silence runncoach 09/06/17 08:18:19 PM
#5384   Why would you say not good enough? runncoach 09/06/17 08:16:04 PM
#5383   Trial results Biostudent 09/06/17 05:10:15 PM
#5382   Nothing that I know of, last trial results XenaLives 09/06/17 03:17:15 PM
#5381   Upcoming event? Biostudent 09/06/17 02:07:08 PM
#5380   Thanks. eom heldnova 08/24/17 11:38:41 AM
#5379   it's post 4967. It's the first sticky note runncoach 08/24/17 08:34:16 AM
#5378   Anyone have a link to the article on heldnova 08/23/17 10:10:48 PM
#5377   Hope so as well. pennymonster1 08/23/17 12:44:00 AM
#5376   Hope so. Could use an update on runncoach 08/22/17 03:16:25 PM
#5375   Could be FragileX trial is getting close to announcement. Whatsupp 08/22/17 02:08:35 PM
#5374   Yes. Better volume since 3 pm yesterday though runncoach 08/22/17 01:27:45 PM
#5373   Volatile! on low volume. Any news good or Biostudent 08/22/17 01:03:37 PM
#5372   Nasdaq site scans 13-F SEC filings from major runncoach 08/16/17 04:35:25 PM
PostSubject